CIK 0001819133
- Non-accelerated filer
- Smaller reporting company
Tango Therapeutics, Inc.
Sign in to watch- Ticker
- TNGX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 857-320-4900
- Business address
- 201 BROOKLINE AVENUE, SUITE 901, BOSTON, MA, 02215
- Former names
- BCTG Acquisition Corp.
- 3 Insider Initial Statement of Ownership
- 4 Planned sale President, R&D sold 38,460 shares at $25.00 ($961,500)
- 4 Planned sale President, R&D sold 27,000 shares at $21.20 ($572,478)
- 4 Planned sale President, R&D sold 12,000 shares at $20.11 ($241,320)
- 4 Planned sale President, R&D sold 20,251 shares at $15.00 ($303,765)
- 4 Planned sale President, R&D sold 54,345 shares at $12.77 ($694,208)
- 4 Open-market sale Chief Financial Officer sold 10,317 shares at an average $12.26 ($126,531)
- 4 Open-market sale Director, Executive Chair sold 30,519 shares at an average $12.26 ($374,294)
- 4 Open-market sale President, R&D sold 18,452 shares at an average $12.26 ($226,300)
- 4 Grant or award President & CEO acquired 350,000 shares (grant or award)
- 4 Grant or award Director acquired 10,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Open-market sale 10% owner sold 477,401 shares at $10.15 ($4,846,575)
- 4 Open-market sale 10% owner sold 500,000 shares at $8.02 ($4,008,500)
- 4 Open-market sale 10% owner sold 363,541 shares at $7.04 ($2,559,329)
- 4 Open-market sale 10% owner sold 729,365 shares at an average $7.00 ($5,108,970)
- 4 Open-market sale 10% owner sold 302,194 shares at $7.00 ($2,115,358)
- 4 Open-market sale 10% owner sold 1,100,000 shares at $7.01 ($7,712,760)
- 4 Grant or award Director acquired 6,250 shares (grant or award)
Page 2 of 8 · 156 filings